StockNews.com initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) in a report issued on Thursday morning. The brokerage issued a buy rating on the stock.

TEVA has been the subject of a number of other research reports. Evercore ISI raised shares of Teva Pharmaceutical Industries from an in-line rating to an outperform rating in a research report on Thursday, May 18th. UBS Group raised shares of Teva Pharmaceutical Industries from a sell rating to a neutral rating and upped their price target for the stock from $7.00 to $8.00 in a research report on Thursday, July 6th. Finally, Morgan Stanley started coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, May 25th. They set an equal weight rating and a $10.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of Hold and a consensus target price of $10.14.

Get Teva Pharmaceutical Industries alerts:

View Our Latest Stock Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Trading Up 0.6 %

Insider Activity

Shares of NYSE:TEVA traded up $0.06 during trading on Thursday, reaching $9.62. The stock had a trading volume of 2,546,671 shares, compared to its average volume of 11,151,416. The business has a fifty day moving average price of $8.35 and a 200-day moving average price of $8.68. The company has a debt-to-equity ratio of 2.43, a quick ratio of 0.67 and a current ratio of 1.02. Teva Pharmaceutical Industries has a fifty-two week low of $7.09 and a fifty-two week high of $11.44.

In other news, insider Eric A. Hughes sold 52,742 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $8.30, for a total value of $437,758.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Eric A. Hughes sold 52,742 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $8.30, for a total value of $437,758.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eliyahu Sharon Kalif sold 35,125 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $9.73, for a total transaction of $341,766.25. Following the transaction, the chief financial officer now owns 99,162 shares in the company, valued at $964,846.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 89,848 shares of company stock worth $799,176. 0.62% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the company. Money Concepts Capital Corp acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $25,000. International Assets Investment Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $26,000. Signaturefd LLC increased its holdings in shares of Teva Pharmaceutical Industries by 85.7% in the 4th quarter. Signaturefd LLC now owns 2,962 shares of the company’s stock worth $27,000 after acquiring an additional 1,367 shares during the period. Quilter Plc acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $3,103,125,000. Finally, Tobam acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $25,000. Institutional investors and hedge funds own 49.69% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Recommended Stories

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.